Overall cancer mortality rates in the United States continued to drop precipitously, falling by 2.4% from 2017-2018, according to the American Cancer Society's latest Cancer Statistics report.
Sean Khozin, a data science expert and formerly a senior medical officer at FDA, has been tapped to lead CancerLinQ—the American Society of Clinical Oncology's multimillion-dollar big data initiative designed to generate real-world evidence from patient records.
FDA is issuing a guidance on FDA's enforcement policy regarding certain quality standards requirements under the Mammography Quality Standards Act of 1992.
McKesson and Amgen signed a strategic agreement to improve cancer care in community oncology settings.
Postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it is added to hormone therapy, according to initial results from a clinical trial presented at the 2020 San Antonio Breast Cancer Symposium.
University of California, Los Angeles-led research shows that behavioral interventions, mindfulness meditation and survivorship education classes, are effective in reducing depressive symptoms in younger breast cancer survivors, who often experience the highest levels of depression, stress and fatigue that can persist for as long as a decade after their diagnosis.
The American Society of Clinical Oncology issued comprehensive recommendations to guide the cancer community's eventual recovery from the COVID-19 pandemic.
A single protein that appears necessary for the COVID-19 virus to reproduce and spread to other cells is a potential weakness that could be targeted by future therapies.
A cancer-killing virus that City of Hope scientists developed could one day improve the immune system's ability to eradicate tumors in colon cancer patients, according to a study in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
Although FY21 funds have not been appropriated for the Department of Defense Ovarian Cancer Research Program, the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY21 funding opportunities.
